UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re: Advanced Bioscience Consumables, Inc. §
§
§
Debtor(s) §

Case No. 23-10368

☐ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 09/30/2025

Petition Date: 03/29/2023

Plan Confirmed Date: 07/19/2023

Plan Effective Date: 08/03/2023

This Post-confirmation Report relates to:
- ○ Reorganized Debtor
- ◉ Other Authorized Party or Entity: Liquidation Trustee
  Name of Authorized Party or Entity

/s/ Katelin A. Morales
Signature of Responsible Party

Katelin A. Morales
Printed Name of Responsible Party

10/21/2025
Date

Potter Anderson & Corroon LLP
1313 N. Market St., 6th Floor
Wilmington, DE 19801-6108
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	$43,412	$705,155
b. Non-cash securities transferred	$0	$0
c. Other non-cash property transferred	$0	$0
d. Total transferred (a+b+c)	$43,412	$705,155

Part 2: Preconfirmation Professional Fees and Expenses

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
a.	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor		*Aggregate Total*	$0	$0	$0	$0
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i			$0	$0	$0	$0
	ii						
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						
	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						
	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
b.	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor *Aggregate Total*			$0	$0	$0	$0
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i			$0	$0	$0	$0
	ii						
	iii						
	iv						
	v						
	vi						

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						
	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						
	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)			$0	$0	$0	$0

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	$0	$0	$0	$0	0%
b. Secured claims	$0	$0	$0	$0	0%
c. Priority claims	$0	$0	$0	$0	0%
d. General unsecured claims	$1,250,000	$0	$0	$36,000,000	0%
e. Equity interests	$0	$0	$0		

Part 4: Questionnaire

a. Is this a final report? Yes ○ No ●

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: 06/30/2026

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ● No ○

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Peter Kravitz	Peter Kravitz
Signature of Responsible Party	Printed Name of Responsible Party
Liquidation Trustee, in his sole capacity	10/21/2025
Title	Date

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

Page 1

Other Page 1

Page 2 Minus Tables

Bankruptcy Table 1-50

Debtor's Name Advanced Bioscience Consumables, Inc. Case No. 23-10368

Bankruptcy Table 51-100

Non-Bankruptcy Table 1-50

Non-Bankruptcy Table 51-100

Part 3, Part 4, Last Page

***In re Advanced Bioscience Consumables, Inc.*,**
Case No. 23-10368

Notes to Post-Confirmation Report for Quarter Ended September 30, 2025

Regarding Part 2: Preconfirmation Professional Fees and Expenses:

Pursuant to the *Joint Chapter 11 Plan of Reorganization of SiO2 Medical Products, Inc., and Its Debtor Affiliates* (the "Plan") and the Liquidation Trust Agreement executed by the Liquidation Trustee and the Debtors (the "Liquidation Trust Agreement"), Peter Kravitz is the duly appointed trustee of the Liquidation Trust. Pursuant to the Plan, the Reorganized Debtors are charged with, among other things, paying Professional Fee Claims to Professionals. *See* Plan, Art. II(B)(1). Accordingly, the Liquidation Trustee has no insight or information regarding the payment of professional fees and expenses.

Regarding Part 3(a) – (c) and (e):

The Liquidation Trustee is charged with, among other things, effectuating the distributions to Holders of Allowed General Unsecured Claims and Holders of Allowed Athos Subordinated Claims. Accordingly, Liquidation Trustee has no insight or information regarding the recoveries of the holders of administrative claims, secured claims, priority claims, or equity interests.

Regarding Part 3(d):

"Total Anticipated Payments Under Plan" reflects cash on hand as of the date of the Effective Date provided to the Trust as per the terms of the Plan. This amount is subject to growth based on litigation proceeds and subject to reduction based on, among other things, operating expenses of the Liquidation Trustee and/or the estates.

The claims reconciliation process is ongoing and reporting with respect to "Allowed Claims" is premature at this time. Accordingly, all of the amounts listed under "Allowed Claims," irrespective of priority level, reflect the estimates set forth in the *Disclosure Statement for the Joint Chapter 11 Plan of Reorganization of SiO2 Medical Products, Inc., and Its Debtor Affiliates* [Docket No. 373]. The Liquidation Trustee reserves all of its rights with respect to the validity, amount, and priority of all claims filed in the chapter 11 cases. Nothing in this post-confirmation report shall constitute an admission that any claim is, in fact, "Allowed." In addition, all amounts are subject to change as the reconciliation process evolves. Therefore, the "% Paid of Allowed Claims" may be inaccurate as a result.

CERTIFICATE OF SERVICE

I, Katelin A. Morales, do hereby certify that on October 21, 2025, a copy of the foregoing ***Chapter 11 Post-Confirmation Report for the Quarter Ending 09/30/2025*** was served on the party listed below in the manner indicated.

United States Trustee
Linda Richenderfer
Email: Linda.Richenderfer@usdoj.gov; ustp.region03@usdoj.gov

Via Email

/s/ Katelin A. Morales
Katelin A. Morales (No. 6683)